Development of Novel Mitochondrial-Targeted Drug Delivery System
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 3
Special Issue Editors
2. UCIBIO—Applied Molecular Biosciences Unit, MedTech—Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, 050-313 Porto, Portugal
Interests: bioactive delivery systems; lipid-based nanosystems; hybrid nanosystems; controlled delivery; multifunctional nanosystems
Special Issues, Collections and Topics in MDPI journals
Interests: drug delivery; nanoparticles; nanomedicine; tissue-specific targeting; tumor targeting
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to our Special Issue on the "Development of Novel Mitochondrial-Targeted Drug Delivery Systems for Rare Genetic Diseases and Cancer Therapy". This issue will explore innovative strategies enhancing drug delivery to the mitochondria, crucial for energy production and apoptosis regulation. Mitochondrial dysfunction is a key factor in many rare genetic diseases and cancers, yet traditional delivery methods often fail to target the mitochondria effectively. We aim to highlight advancements such as liposomal delivery systems, peptide-based targeting, nanoparticle-based systems, and mitochondria-penetrating peptides (MPPs), which promise significant therapeutic benefits. These approaches can improve muscle function in mitochondrial myopathies, slow disease progression in Leigh syndrome, and reduce oxidative stress in Friedreich's ataxia. In cancer therapy, mitochondrial-targeted systems can induce apoptosis, overcome drug resistance, and selectively kill cancer cells through targeted oxidative stress. We seek submissions addressing challenges like stability, biocompatibility, targeting efficiency, scaling up production, and understanding the long-term effects. Papers proposing novel targeting ligands, optimizing drug loading, and presenting comprehensive preclinical and clinical data are encouraged, alongside contributions integrating advanced technologies such as CRISPR-based genome editing and personalized medicine approaches. Your research will help advance this promising field and potentially revolutionize treatments for rare genetic diseases and cancer.
We look forward to your valuable contributions.
Dr. Carla Martins Lopes
Dr. Pankaj Dwivedi
Dr. Uner Burcu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mitochondrial-targeted drug delivery
- rare genetic diseases
- cancer therapy
- liposomal delivery systems
- peptide-based targeting
- nanoparticle-based systems
- mitochondria-penetrating peptides (MPPs)
- mitochondrial dysfunction
- apoptosis induction
- drug resistance
- oxidative stress
- targeting ligands
- CRISPR-based genome editing
- personalized medicine approaches
